MicroRNA-132 modulates cholinergic signaling and inflammation in human inflammatory bowel disease

Inflammatory Bowel Diseases

Volumn 19, Issue 7, 2013, Pages 1346-1353

  Maharshak, Nitsan ^a   Shenhar Tsarfaty, Shani ^a,b   Aroyo, Nimrod ^a   Orpaz, Naama ^a   Guberman, Irene ^b   Canaani, Jonathan ^a   Halpern, Zamir ^a   Dotan, Iris ^a   Berliner, Shlomo ^a   Soreq, Hermona ^b  

^a TEL AVIV UNIVERSITY   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Acetylcholinesterase; Cholinergic status; Colitis; MicroRNA; Vagal tone

Indexed keywords

ACETYLCHOLINE; ACETYLCHOLINESTERASE; ARYLDIALKYLPHOSPHATASE; C REACTIVE PROTEIN; MICRORNA 132;

ADOLESCENT; ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CHOLINERGIC TRANSMISSION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; ENTERITIS; ENZYME ACTIVITY; FEMALE; HOMEOSTASIS; HUMAN; HUMAN TISSUE; INFLAMMATION; INTESTINE BIOPSY; MALE; NEUROMODULATION; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; VAGUS TONE;

ACETYLCHOLINESTERASE; ADOLESCENT; ADULT; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CHILD; FEMALE; HUMANS; INFLAMMATION; INFLAMMATORY BOWEL DISEASES; INTESTINAL MUCOSA; MALE; MICRORNAS; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; SIGNAL TRANSDUCTION; YOUNG ADULT;

EID: 84879073845     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0b013e318281f47d     Document Type: Article

References (38)

1. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010;362:1383-1395.
2. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002;359:1541-1549.
3. Tracey KJ. The inflammatory reflex. Nature. 2002;420:853-859.
4. Wang H, Yu M, Ochani M, et al. Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. Nature. 2003;421:384-388.
5. De Jonge WJ, Van der Zanden EP, The FO, et al. Stimulation of the vagus nerve attenuates macrophage activation by activating the Jak2-STAT3 signaling pathway. Nat Immunol. 2005;6:844-851.
6. Metz CN, Tracey KJ. It takes nerve to dampen inflammation. Nat Immunol. 2005;6:756-757.
7. Borovikova LV, Ivanova S, Nardi D, et al. Role of vagus nerve signaling in CNI-1493-mediated suppression of acute inflammation. Auton Neurosci. 2000;85:141-147.
8. Rosas-Ballina M, Olofsson PS, Ochani M, et al. Acetylcholine-synthesizing T cells relay neural signals in a vagus nerve circuit. Science. 2011;334:98-101.
9. Huston JM, Rosas-Ballina M, Xue X, et al. Cholinergic neural signals to the spleen down-regulate leukocyte trafficking via CD11b. J Immunol. 2009;183:552-559.
10. Ofek K, Krabbe KS, Evron T, et al. Cholinergic status modulations in human volunteers under acute inflammation. J Mol Med (Berl). 2007;85:1239-1251.
11. Sklan EH, Lowenthal A, Korner M, et al. Acetylcholinesterase/paraoxonase genotype and expression predict anxiety scores in Health, Risk Factors, Exercise Training, and Genetics study. Proc Natl Acad Sci U S A. 2004;101:5512-5517.
12. Tili E, Michaille JJ, Cimino A, et al. Modulation of miR-155 and miR-125b levels following lipopolysaccharide/TNF-alpha stimulation and their possible roles in regulating the response to endotoxin shock. J Immunol. 2007;179:5082-5089.
13. Shaked I, Meerson A, Wolf Y, et al. MicroRNA-132 potentiates cholinergic anti-inflammatory signaling by targeting acetylcholinesterase. Immunity. 2009;31:965-973.
14. Meregnani J, Clarencon D, Vivier M, et al. Anti-inflammatory effect of vagus nerve stimulation in a rat model of inflammatory bowel disease. Auton Neurosci. 2011;160:82-89.
15. Ghia JE, Blennerhassett P, Kumar-Ondiveeran H, et al. The vagus nerve: a tonic inhibitory influence associated with inflammatory bowel disease in a murine model. Gastroenterology. 2006;131:1122-1130.
16. McCafferty DM, Wallace JL, Sharkey KA. Effects of chemical sympathectomy and sensory nerve ablation on experimental colitis in the rat. Am J Physiol. 1997;272:G272-G280.
17. Bai A, Guo Y, Lu N. The effect of the cholinergic anti-inflammatory pathway on experimental colitis. Scand J Immunol. 2007;66:538-545.
18. Ganguli SC, Kamath MV, Redmond K, et al. A comparison of autonomic function in patients with inflammatory bowel disease and in healthy controls. Neurogastroenterol Motil. 2007;19:961-967.
19. Maharshak N, Arbel Y, Bornstein NM, et al. Inflammatory bowel disease is not associated with increased intimal media thickening. Am J Gastroenterol. 2007;102:1050-1055.
20. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462-2476.
21. Conroy CA, Cattell R. Infliximab treatment for Crohn's disease. Postgrad Med J. 2001;77:436-440.
22. Clauss A. [Rapid physiological coagulation method in determination of fibrinogen]. Acta Haematol. 1957;17:237-246.
23. Rifai N, Tracy RP, Ridker PM. Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clin Chem. 1999;45:2136-2141.
24. Ben Assayag E, Shenhar-Tsarfaty S, Ofek K, et al. Serum cholinesterase activities distinguish between stroke patients and controls and predict 12-month mortality. Mol Med. 2010;16:278-286.
25. Ellman GL, Courtney KD, Andres V Jr, et al. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol. 1961;7:88-95.
26. Stojanov MD, Jovicic DM, Djuric SP, et al. Butyrylcholinesterase activity and mortality risk in hemodialysis patients: comparison to hsCRP and albumin. Clin Biochem. 2009;42:22-26.
27. Calderon-Margalit R, Adler B, Abramson JH, et al. Butyrylcholinesterase activity, cardiovascular risk factors, and mortality in middleaged and elderly men and women in Jerusalem. Clin Chem. 2006;52:845-852.
28. Ben Assayag E, Korczyn AD, Giladi N, et al. Predictors for poststroke outcomes: the Tel Aviv Brain Acute Stroke Cohort (TABASCO) study protocol. Int J Stroke. 2011;7:341-347.
29. Pullan RD, Rhodes J, Ganesh S, et al. Transdermal nicotine for active ulcerative colitis. N Engl J Med. 1994;330:811-815.
30. Green JT, Thomas GA, Rhodes J, et al. Nicotine enemas for active ulcerative colitis-a pilot study. Aliment Pharmacol Ther. 1997;11:859-863.
31. Lakhan SE, Kirchgessner A. Anti-inflammatory effects of nicotine in obesity and ulcerative colitis. J Transl Med. 2011;9:129.
32. Lakhan SE, Kirchgessner A. Neuroinflammation in inflammatory bowel disease. J Neuroinflammation. 2010;7:37.
33. Lampon N, Hermida-Cadahia EF, Riveiro A, et al. Association between butyrylcholinesterase activity and low-grade systemic inflammation. Ann Hepatol. 2012;11:356-363.
34. Aviram M, Rosenblat M, Bisgaier CL, et al. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J Clin Invest. 1998;101:1581-1590.
35. Charania MA, Ayyadurai S, Ingersoll SA, et al. Intestinal epithelial CD98 synthesis specifically modulates expression of colonic microRNAs during colitis. Am J Physiol Gastrointest Liver Physiol. 2012;302:G1282-G1291.
36. Paraskevi A, Theodoropoulos G, Papaconstantinou I, et al. Circulating MicroRNA in inflammatory bowel disease. J Crohns Colitis. 2012;6:900-904.
37. Koch TR, Schulte-Bockholt A, Telford GL, et al. Acquired megacolon is associated with alteration of vasoactive intestinal peptide levels and acetylcholinesterase activity. Regul Pept. 1993;48:309-319.
38. Wanet A, Tacheny A, Arnould T, et al. miR-212/132 expression and functions: within and beyond the neuronal compartment. Nucleic Acids Res. 2012;40:4742-4753.